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Background: Antidepressants are widely used in the treatment of chronic pain. Applied 
doses are lower than those needed to unfold an antidepressive effect. While efficacy of 
antidepressants for chronic pain has been reported in large randomized-controlled trials 
(RCT), there is inconsistent data on adverse effects and tolerability. We aimed at synthe-
sizing data from RCT to explore adverse effect profiles and tolerability of antidepressants 
for treatment of chronic pain.
Methods: Systematic literature research and meta-analyses were performed regarding 
side effects and safety of different antidepressants in the treatment of chronic pain accord-
ing to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 
The National Center for Biotechnology Information library and MEDLINE were searched. 
Randomized placebo-controlled trials were included in quantitative data synthesis.
results: Out of 1,975 screened articles, 33 papers published between 1995 and 
2015 were included in our review and 23 studies were included in the meta-analyses. 
A higher risk for adverse effects compared to placebo was observed in all antidepres-
sants included in our analyses, except nortriptyline. The most prevalent adverse effects 
were dry mouth, dizziness, nausea, headache, and constipation. Amitriptyline, mirtazap-
ine, desipramine, venlafaxine, fluoxetine, and nortriptyline showed the highest placebo 
effect-adjusted risk of adverse effects. Risk for withdrawal due to adverse effects was 
highest in desipramine (risk ratio: 4.09, 95%-confidence interval [1.31; 12.82]) followed 
by milnacipran, venlafaxine, and duloxetine. The most common adverse effects under 
treatment with antidepressants were dry mouth, dizziness, nausea, headache, and con-
stipation followed by palpitations, sweating, and drowsiness. However, overall tolerability 
was high. Each antidepressant showed distinct risk profiles of adverse effects.
conclusion: Our synthesized data analysis confirmed overall tolerability of low-dose 
antidepressants for the treatment of chronic pain and revealed drug specific risk profiles. 
This encompassing characterization of adverse effect profiles might be useful in defining 
multimodal treatment regimens for chronic pain which also consider patients’ comorbid-
ities and co-medication.
Keywords: antidepressants, side effects, safety, chronic pain, amitriptyline, nortriptyline, venlafaxine, fluoxetine
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inTrODUcTiOn
Chronic pain is a prevalent condition which affects 36% of the 
population in US (19% in Europe, respectively) and reduces qual-
ity of life. Moreover, it constitutes a considerable socioeconomic 
burden due to health-care resource consumption with annual 
costs of up to $43 billion per year (1, 2). Treatment of chronic 
pain is challenging since etiologies are heterogeneous, including 
inter alia diabetic neuropathy, osteoarthritis, fibromyalgia, and 
headache syndromes such as migraine (3).
While multimodal treatment regimens including both phar-
macological and non-pharmacological interventions are most 
effective in the treatment of chronic pain, pain medication is 
still the second most prescribed group of drugs in the US alone, 
accounting for 12% of all prescriptions (2). Traditional agents, such 
as opioids and non-steroidal anti-inflammatory drugs (NSAIDs), 
are efficacious in the treatment of chronic pain but they are 
limited by adverse effects, tolerance, and potential for addiction. 
Although not specifically intended to treat chronic pain, various 
antidepressants were shown in large randomized-controlled trials 
(RCT) to be efficacious in the treatment of chronic pain conditions, 
such as diabetic neuropathy or migraine (1). Notably, required 
dosages to achieve an analgesic effect are lower than those needed 
to unfold an antidepressive effect. However, there is inconsist-
ent data on adverse effects and tolerability of antidepressants in 
the treatment of chronic pain. This is clinically relevant since 
patients with chronic pain are frequently treated with multiple 
drugs, leading to increased risk of drug interactions and additive 
adverse effects (4, 5). Additionally, neither analgesic mechanisms 
of action of antidepressants nor pathophysiology of chronic pain 
are fully elucidated, highlighting the necessity of improving our 
knowledge on clinical adverse effects of these drugs (6, 7).
Adverse effect profiles of antidepressants may differ based on 
their specific pharmacodynamic and pharmacokinetic charac-
teristics, an overview of which is given in Tables S1 and S2 in 
Supplementary Material.
Meta-analyses of efficacy and safety exist for specific antide-
pressants. We aimed to undertake an encompassing synthesized 
analysis of adverse effects of the most widely used antidepressants 
in the treatment of chronic pain. In particular, we sought to evalu-
ate tolerability and risk of adverse effects related to antidepres-
sants in the therapy of chronic pain.
MaTerials anD MeThODs
literature search strategy
We performed a systematic review and meta-analysis accord-
ing to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines. We systematically searched the 
literature using the search strings “antidepressants AND/in 
chronic pain,” “safety of antidepressants in chronic pain,” and 
“side effects of antidepressants in chronic pain” using the data-
bases of the National Center for Biotechnology Information, the 
National Library of Medicine (MEDLINE), Google Scholar, and 
the Cochrane Central Register of Controlled Trials. Our literature 
search included studies from the first data available until the last 
search conducted in October 2015. However, due to the fact 
that treatment regimens changed over the last decades, studies 
published earlier than 1995 were excluded. Language restriction 
was applied including only articles in German and English.
The retrieved abstracts were stratified according to their 
relevance to the subject, and the full text of articles on the use of 
antidepressants in the treatment of chronic pain was retrieved. 
Additional articles were identified by cross-searching of the 
bibliographies of these publications. Case reports were excluded 
from the analysis. Trials that were included had to be conducted 
to study the use of antidepressants in the treatment of chronic 
pain and at least had to report on adverse effects of the treatment.
study selection criteria
According to the PICO guideline, we included an original study 
in our meta-analysis if the following eligibility criteria were met.
Population of Interest
Population of interest included patients with chronic pain being 
neuropathic, inflammatory/joint-related, or non-inflammatory/
non-neuropathic pain. Pain conditions included in the analyses 
are detailed in Appendix S App-1 in Supplementary Material.
Intervention
The exposure variable (i.e., intervention) was defined as any anti-
depressant that was used for treatment of chronic pain. Specific 
antidepressants were only included in our meta-analysis when 
at least two RCT reporting adverse effects of the corresponding 
antidepressant were available. The study design was restricted to 
randomized placebo-controlled trials. Both constant and incre-
mental dosing protocols were accepted. Both single and adjuvant 
use of antidepresants were accepted.
Control
The control group consisted of patients with chronic pain treated 
with placebo.
Outcome
Outcome parameters comprised any side effects that patients 
experienced during the follow-up period and tolerability that 
was defined as study discontinuation related to antidepressant 
therapy. We included only studies that reported quantitative data 
on adverse effects. We did not differentiate whether outcome 
data were reported as primary or secondary variable. In addition, 
for each included antidepressant, we analyzed pre-defined side 
effects and their relative risk of occurrence.
Data extraction
We extracted data on the number of included patients, the drug 
used as therapy and the occurrence side effects. The data collec-
tion and assessment of methodological quality were conducted 
as previously reported (8). The conduct and reporting were in 
accordance with the Quality of Reporting of Meta-Analyses 
statement.
statistical analysis
The meta-analysis was performed using the statistical software 
R (©The R Foundation). Differences in incidences of overall 
adverse effects, withdrawal due to adverse effects, and specific 
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adverse effects between the respective study arms were sub-
sumed as pooled risk differences (RDs) or risk ratios (RRs) with 
95%-confidence intervals (CIs) based on the random effects 
model of DerSimonian and Laird (9, 10). In addition, if sufficient 
metadata were available, 95% prediction intervals were reported. 
Prediction intervals estimate the range of effects expected to 
occur in future individual studies within the same study popu-
lation. Complementary effect heterogeneity assessments were 
performed using forest plots and the inconsistency statistics (I2). 
Heterogeneity was evaluated by an analysis of the comparability 
of the following items: the number of patients, the grade or stage 
of disease, and the type of applied drug. In case of two drug 
doses per drug and trial, analysis was performed as two separate 
trials using the same placebo group. Conclusions regarding 
presence of evidence of effects were based on confidence and 
prediction interval limits rather than on statistical tests.
Inconclusive evidence occurred if the observed effect was 
close to RR  =  1 and both CI limits would exceed clinically 
relevant margins of RR =  0.8 and RR =  1.2 (marked as: ±). 
Hence, intervals not exceeding either margin were interpreted as 
being supportive for evidence of possible RDs in the respective 
direction (marked as ++ or−−). Strongest evidence for an effect 
was provided if the associated prediction intervals met the same 
criterion (marked as +++ or −−−). In situations where RR esti-
mates would be clinically relevant (exceeding the pre-specified 
margins), however, with wide CI limits exceeding both relevance 
margins, weak evidence for an effect was indicated (marked as + 
or −). Evidence of absence of an effect was indicated if the CI for 
the RR would exclude both margins (marked as 0).
resUlTs
literature search
The MEDLINE search using above mentioned search terms 
revealed 1,975 articles published between 1982 and 2015. Of 1,613 
articles in humans, 255 involved clinical trials whereas 158 were 
designed as RCT. No additional articles than those retrieved with 
the National Center for Biotechnology Information/National 
Library of Medicine databases were found using Google Scholar 
or Cochrane Central Register of Controlled Trials.
One study was excluded because of using the identical study 
population for two trials with different study aims. Another study 
was excluded because study population was restricted to children. 
Of 158 studies, 69 eventually met our selection criteria, and the 
full text articles of these were retrieved. Further selection excluded 
36 studies without reporting quantitatively about occurrence of 
adverse effects. Finally, 33 clinical trials reporting on adverse effects 
were included in our quantitative data analysis. Ten trials had to be 
excluded for meta-analyses due to missing placebo control group, 
and 23 studies were included in the meta-analyses (Figure 1).
adverse effects under Treatment with 
antidepressants: studies included in the 
systematic review and Meta-analysis
Studies that met our inclusion criteria for systematic review 
and meta-analysis comprised clinical trials on amitryptiline, 
nortriptyline, desipramine, milnacipran, venlafaxine, duloxetine, 
mirtazapine, and fluoxetine. Tables S1 and S2 in Supplementary 
Material provide an overview of included antidepressants and 
their pharmacodynamic and pharmacokinetic characteristics. 
Table 1 provides an overview of included studies and their design.
Amitriptyline
Goldman et al. compared amitriptyline (25 mg/day) and placebo 
in the treatment of chronic arm pain in 118 patients. 107 patients 
completed the trail. Overall adverse effects occurred in 31/59 
patients (52%) under amitriptyline and in 16/59 patients (27%) 
under placebo [RD +25% CI: +6%; +42%]. Withdrawal due to 
adverse effects was necessary in the amitriptyline-group in 2/59 
patients (3%) [RD +3% CI: −4%; +12%]. The main side effect 
was drowsiness (11). Similarly, Cardenas et al. reported adverse 
effects of amitriptyline (10–125 mg/day) and placebo in the treat-
ment of pain related to spinal cord injury in 84 patients. Overall 
adverse effects occurred in 43/44 patients (97%) in the amitrip-
tyline group and 36/40 patients (90%) in the placebo group [RD 
+7% CI: −5%; +22%]. Withdrawal due to adverse effects was 
necessary in 7/44 patients (16%) in the amitriptyline and 2/40 
patients (5%) in the placebo group [RD +11% CI: −5%; +26%]. 
Drowsiness, constipation, and dry mouth were the most frequent 
adverse effects. Less often, headache, palpitations, and irritability 
as well as blurred vision were reported (12). Another placebo-
controlled trial, published by Rani et al., compared adverse effects 
of amitriptyline (25 mg/day), fluoxetine (20 mg/day), and placebo 
in 59 patients with chronic pain syndromes. Reported adverse 
effects occurred 31 times in 20 patients under amitriptyline, 22 
times in 21 patients under fluoxetine, and 12 times in 18 patients 
under placebo. Withdrawal due to adverse effects was not neces-
sary. Reported adverse effects of amitriptyline were mainly diz-
ziness, constipation, headache, and palpitations (13). Similarly, 
Bendtsen et al. compared the treatment of amitriptyline (75 mg/
day), citalopram (20 mg/day), and placebo in 40 patients under 
crossover conditions. Under treatment with amitriptyline, 33/40 
patients (82%) reported adverse effects, whereas 15/40 patients 
(37%) under treatment with citalopram and 15/40 patients 
(37%) under placebo [RD +45% CI: +22%; +62%] reported 
adverse effects, 1/40 (2%) patient had to be withdrawn due to 
adverse effects under amitriptyline [RD +2% CI: −9%; +15%]. 
Drowsiness and dry mouth were the main adverse effects, fol-
lowed by dizziness and constipation and gain of body weight (14). 
Boline et al. compared amitriptyline with spinal cord manipula-
tion in the treatment of chronic tension-type headaches in 150 
patients. 46/75 patients (61%) vs. 3/75 patíents (4%) reported 
about adverse effects in the amitriptyline group [RD +57% CI: 
+43%; +68%]. Withdrawal due to adverse effects was necessary 
in 5/75 (7%), while no withdrawal was necessary in the spinal 
manipulation group [RD +7% CI: −1%; +15%]. Main adverse 
effects of amitriptyline were drowsiness and dry mouth (15).
Nortriptyline
Khoromi et al. compared nortriptyline (25–100 mg/day), mor-
phine (15–90  mg/day), and active placebo benztropine in the 
treatment of lumbar radicular pain in patients. Overall adverse 
effects were reported in 9/13 patients (68%) in the nortriptyline 
FigUre 1 | Flow chart of selection of trials included in the meta-analyses.
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TaBle 1 | Placebo-controlled randomized clinical trials comparing antidepressants with placebo in the treatment of chronic pain.
Goldman et al. (11) Amitriptyline  
(25 mg/day)
6 weeks Arm pain due to 
repetitive use
1. n = 59 1. n = 52 1. n = 31/59 (52%) 1. n = 2/59 (3.4%) Drowsiness
3. n = 59 3. n = 55 3. n = 16/59 (27%) 3. n = 0
Cardenas et al. (12) RCT Amitriptyline  
(10–125 mg/day)
6 weeks Pain of spinal cord injury 1. n = 44 1. n = 37 1. n = 43/44 (97%) 1. n = 7/44 (16%) Dry mouth, drowsiness, urinary 
difficulty,  
constipation, sweating, 
headache, irritability, 
palpitations, diarrhea, blurred 
vision
DB 3. n = 40 3. n = 38 3. n = 36/40 (90%) 3. n = 2/40 (5%)
Rani et al. (13) RCT 1. Amitriptyline  
(25 mg/day)
4 weeks Chronic pain syndrome 
(27 low-back pain, 16 
osteoarthritis,  
8 FM, 8 rheumatoid 
arthritis)
1. n = 20 1. n = 31 Dizziness, constipation, 
headache, palpitations, edema, 
gastritis, thirst, tachycardiaDB 2. Fluoxetine  
(20 mg/day)
2. n = 21 2. n = 22
3. n = 18 3. n = 12
Bendtsen et al. (14) RCT Amitriptyline  
(25–75 mg/day) vs. 
citalopram  
(20 mg/day)
32 weeks (8 weeks tx, 
2 weeks wash-out)
Tension-type headache 1. n = 40 1. n = 33/40 (82%) 1. n = 1/40 (2%) Dry mouth, drowsiness, 
dizziness, weight gain, nausea, 
constipation
DB 2. n = 40 2. n = 15/40 (37%) 2. n = 0
3w-CO 3. n = 40 3. n = 15/40 (37%) 3. n = 0
Boline et al. (15) RCT Amitriptyline  
(10–30 mg/day) vs.  
spinal manipulation
6 weeks Tension-type headache 1. n = 75 1. n = 56 1. n = 46/75 (61%) 1. n = 5/75 (7%) Drowsiness, dry mouth, weight 
gain3. n = 75 3. n = 70 3. n = 3/75 (4%) 3. n = 0
Khoromi et al. (16) RCT Nortriptyline  
(25–100 mg/day) vs. 
morphine
9 weeks (5 weeks 
dose  
escalation, 2 weeks 
maintain-ance, 
2 weeks tapering)
Chronic lumar root pain 1. n = 13 1. n = 7 1. n = 9/13 (37%) 1. n = 2/13 (15%) Constipation, dry mouth, 
drowsiness, dizziness, 
somnolence, headache, 
insomnia, weight gain,  
urinating difficulty, abdominal 
pain, heart burn
DB 2. n = 15 2. n = 9 2. n = 14/15 (93%) 2. n = 5/15 (7%)
CO 3. n = 13 3. n = 5 3. n = 4/5 (31%) 3. n = 4/13 (31%)
SC
Holroyd et al. (17) RCT Nortriptyline  
(75 mg/day  
or amitriptyline 100 mg/
day)
8 weeks Chronic tension-type 
headache
1. n = 97 1. n = 53 1. n = 78/97 (80%) 1. n = 1/97 (1%) Drowsiness, dry mouth, 
dizziness, constipation,  
weight gain, abdominal pain, 
increased appetite
DB 3. n = 90 3. n = 48 3. n = 27/90 (23%) 3. n = 3/90 (3%)
Atkinson et al. (18) RCT Nortriptyline (escalating 
25–50–100 mg/dl)
8 weeks Chronic low-back  
pain
1. n = 38 1. n = 28 1. n = 28/38 (74%) 1. n = 4/38 (10%) Dry mouth, insomnia,  
sedation, orthostatic 
hypotension, constipation, 
sweating, palpitations
DB 3. n = 40 3. n = 29 3. n = 28/40 (70%) 3. n = 0/40
Atkinson et al. (19) RCT Desipramine (50–110–
150 ng/ml levels) vs. 
Fluoxetine
12 weeks Chronic back pain 1. n = 52 1. n = 30 1. n = 19/30 (63%) 1. n = 17/52 (33%) Decreased salivation, 
constipation, loss of libidoDB 2. n = 43 2. n = 31 2. n = 16/31 (53%) 2. n = 3/43 (7%)
SC 3. n = 26 3. n = 22 3. n = 3/22 (14%) 3. n = 1/26 (4%)
Wallace et al. (20) RCT Desipramine (escalating 
50–300 mg/day)
35 weeks (14 weeks 
tx)
Capsicain-induced 
allodynia
1. n = 12 1. n = 5/12 (42%) 1. n = 1/13 (8%) Constipation, dry mouth, 
vomiting, drowsiness, 
dizziness, sweating, headache, 
insomnia, shaking
DB 3. n = 12 3. n = 0/12 3. n = 0/13
CO
Clauw et al. (21) RCT Milnacipran (100 mg/day) 12 weeks Fibromyalgia 1. 
n = 100
1. n = 75 1. n = 47/100 (47%) 1. n = 2/100 (2%) Nausea, vomiting, headache, 
sinusitis/nasopharyngitis, 
respiratory infection, fatigue, 
fall, arthralgia, edema
DB 3. n = 50 3. n = 31 3. n = 29/50 (58%) 3. n = 0
MC
(Continued)
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Mease et al. (22) RCT Milnacipran (100 mg/day; 
200 mg/day)
27 weeks Fibromyalgia 1. n = 224 1. n = 128 1. n = 188/224 (84%) 1. n = 44/224 (20%) Nausea, vomiting, dizziness, 
constipation, headache, 
tachycardia, palpitations, 
hot flush, dry mouth, 
sweating, insomnia, sinusitis, 
nasopharyngitis, respiratory 
infection, diarrhea
DB 2. n = 441 2. n = 239 2. n = 400/441 (90%) 2. n = 119/441 (27%)
MC 3. n = 223 3. n = 145 3. n = 190/223 (85%) 3. n = 23/223 (10%)
Clauw et al. (23) RCT Milnacipran (100 mg/day; 
200 mg/day)
15 weeks Fibromyalgia 1. n = 401 1. n = 399 1. n = 358/401 (90%) 1. n = 78/401 (20%) Nausea, vomiting, dizziness, 
constipation, headache, 
hypertension, tachycardia, 
palpitations, hot flush
DB 2. n = 401 2. n = 396 2. n = 346/401 (87%) 2. n = 94/401 (24%)
MC 3. n = 405 3. n = 401 3. n = 317/405 (79%) 3. n = 38/405 (9%)
Ozyalcin et al. (24) RCT Venlafaxine XR (75 mg/day; 
150 mg/day)
8 weeks Migraine 1. n = 20 1. n = 15 1. n = 20/20 (100%) 1. n = 3/20 (15%) Nausea, vomiting, drowsiness, 
dizziness, somnolence, 
mydriasis, jaw spasm, 
constipation, loss of libido, 
dry mouth, sweating, loss of 
appetite, sedation
2. n = 21 2. n = 17 2. n = 20/21 (95%) 2. n = 3/21 (14%)
3. n = 19 3. n = 17 3. n = 10/19 (53%) 3. n = 0/19 
Yucel et al. (25) RCT Venlafaxine XR (75 mg/day; 
150 mg/day)
8 weeks Neuropathic pain 1. n = 20 1. n = 19 1. n = 9/20 (45%) 1. n = 1/20 (5%) Nausea, vomiting, dizziness, 
somnolenceDB 2. n = 20 2. n = 17 2. n = 14/20 (70%) 2. n = 3/20 (15%)
3. n = 20 3. n = 19 3. n = 11/20 (55%) 3. n = 1/20 (5%)
Forssell et al. (26) R Venlafaxine (37.5 mg 1–2×/
day)
10 weeks (4 weeks tx) Atypical facial pain 1. n = 30 1. n = 20 1. n = 18/30 (60%) 1. n = 6/30 (20%) Nausea, constipation, dry 
mouth, sweating, loss of 
appetite, urinating difficulty, 
fatigue, nightmares, headache, 
palpitations
DB 3. n = 30 3. n = 20 3. n = 18/30 (60%) 3. n = 2/30 (7%)
CO
Chappell et al. (27) RCT Duloxetine (60–120 mg/
day)
13 weeks Osteoarthritis of the 
knee
1. n = 128 1. n = 93 1. n = 64 (50%) 1. n = 24/128 (19%) Nausea, constipation, 
hyperhidrosisDB 3. n = 128 3. n = 111 3. n = 41 (32%) 3. n = 7/128 (5%)
Ho et al. (28) RCT Duloxetine 60 mg 2 h before surgery; d1 
after surgery
Knee replacement 
surgery
1. n = 23 N = 0 1. n = 6/23 (26%) N = 0 Nausea, dizziness, headache, 
pruritusDB 3. n = 24 3. n = 12/24 (50%)
Skljarevski et al. (30) RTC Duloxetine (60 mg/day) 12 weeks Chronic low-back pain 1. n = 198 1. n = 147 1. n = 125/198 (63%) 1. n = 30/198 (15%) Nausea, dizziness, 
somnolence, headache, 
constipation, dry mouth, 
vertigo, myocardial infarction, 
muscular weakness, asthma
DB 3. n = 203 3. n = 156 3. n = 112/203 (55%) 3. n = 11/203 (5%)
Skljarevski et al. (31) RCT Duloxetine (60–120 mg/
day)
13 weeks Chronic low-back pain 1. n = 115 1. n = 84 1. n = 65/115 (57%) 1. n = 16/115 (14%) Nausea, dizziness,  
somnolence, headache, dry 
mouth, fatigue, diarrhea, 
Hyperhidrosis, TIA, 
osteoarthritis, constipation
DB 3. n = 121 3. n = 98 3. n = 58/121 (48%) 3. n = 7/121 (6%)
Skljarevski et al. (29) RCT Duloxetine [(1.) 20mg/
day, (2.) 60 mg/day or (2*.) 
120 mg/day]
13 weeks Chronic low-back pain 1. n = 59 1. n = 43 1. 64.4% 1. n = 9/59 (15%) TIA, myocardial infarction, 
dyspnoe, weakness, diarrhea, 
dizziness
DB 2. 
n = 116
2. n = 80 2. 67.2% 2. n = 17/116 (15%)
2*. 
n = 112
2*. n = 62 2*. 72.3% 2*. n = 27/112 (24%)
3. 
n = 117
3. n = 82 3. 59% 3. n = 10/117 (9%)
TaBle 1 | Continued
(Continued)
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group, in 14/15 patients (93%) in the morphine group, and 
6/13 patients (50%) in the placebo group [RD +23% CI: −18%; 
+56%]. Withdrawal due to adverse effects was necessary in 2/13 
patients (15%) in the nortriptyline group, 5/15 patients (7%) 
in the morphine group, and 1/14 patients (7%) in the placebo 
group [RD +8% CI: −23%; +40%]. Main adverse effects in the 
nortriptyline group were constipation and dry mouth, followed 
by somnolence, dizziness, drowsiness, headache, insomnia, 
weight gain, and heart burn (16). Comparison of amitryptiline 
(100 mg/day) or nortriptyline (75 mg/day) and placebo in the 
treatment of chronic tension-type headaches was performed by 
Holroyd et al. Noteworthy, authors analyzed effects and adverse 
effects of amitriptyline and nortriptyline as one “treatment” 
group compared to the placebo group. 78/97 patients (80%) in 
the treatment group had adverse effects as opposed to 27/90 
patients (23%) in the placebo group [RD +50% CI: +36%; 
+62%]. Withdrawal due to adverse effects was necessary in 
1/97 (1%), but 3/90 (3%) in the placebo group [RD +2% CI: 
−3%; +9%]. The main adverse effects were drowsiness (44%) 
and dry mouth (53%) compared to placebo group with 11 and 
13%, respectively (17). Atkinson et al. compared nortriptyline 
at escalating doses (25 up to 100 mg/day) with inert placebo in 
the treatment of chronic back pain in 78 patients. 57 patients 
completed the study. In the treatment group 28/28 patients 
(100%) analyzed patients participating in the trail reported 
adverse effects whereas 28/29 patients (97%) reported adverse 
effects under placebo [RD +4% CI: −18%; +24%]. However, 
withdrawal due to adverse effects was necessary in 4/38 patients 
(10%) under therapy with nortriptyline, but was not necessary 
in the placebo group [RD +10% CI: −2%; +26%]. Main adverse 
effects were constipation, dry mouth and insomnia, sedation, 
sweating, palpitations, and orthostatic hypotension in the nor-
triptyline group. Adverse effects were reported more frequently 
in the nortriptyline group (18).
Desipramine
Atkinson et  al. compared the treatment of desipramine, 
fluoxetine, and placebo for the treatment of chronic low-back 
pain in 121 patients. Doses were adjusted to measured blood 
concentration of the specific drugs. Three different subgroups 
according to blood concentrations of desipramine (levels of 50, 
110, and 150 ng/ml) and fluoxetine (blood levels of 100, 200, and 
400 ng/ml) were included. Overall adverse effects were reported 
in 19/39 patients (63%) for desipramine, 16/31 patients (53%) 
for fluoxetine, and 3/22 patients (14%) for placebo [RD +50% 
CI: +20%; +69%]. The study was completed by 83 out of 121 
patients. Withdrawal due to adverse effects was necessary in 
17/52 patients (33%) under desipramine and in 1/26 patients 
(4%) under placebo [RD +29% CI: +7%; +44%]. Adverse effects 
were similar for patients with desipramine blood concentra-
tions lesser or greater than 60 ng/ml. The main adverse effects 
for desipramine were dry mouth and constipation, whereas 
fluoxetine mainly led to sexual disturbances (19). In a crossover 
trial by Wallace et al., allodynia was induced by capsicain in 12 
healthy patients and treatment with desipramine at escalating 
doses (50 up to 300 mg/day within 14 days) was compared with 
placebo. Adverse effects occurred in 5/12 (42%) patients vs. 0/12 
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in the placebo group [RD +42% CI: +2%; +71%]. One with-
drawal due to adverse effects [1/13; (7.6%)] was reported in the 
desipramine group [RD +8% CI: −21%; +38%]. The two most 
common adverse effects were dry mouth and drowsiness. Fewer 
adverse effects were sweating, headache, shaking, insomnia, 
nausea, vomiting, and constipation (20).
Milnacipran
Clauw et al. analyzed the treatment of milnacipran at 100 mg/day 
in the treatment of fibromyalgia in 150 patients. Overall adverse 
effects were reported in 47/100 (47%) patients in the milnacip-
ran group and in 29/50 patients (58%) in the placebo group 
[RD +11% CI: −7%; +28%]. Main adverse effects were nausea, 
vomiting, headache, nasopharyngitis and respiratory infections, 
fatigue, fall, arthralgia, and edema. Similar adverse effects were 
also reported in the placebo group. Adverse effect-related discon-
tinuation was necessary in 2/100 patients (2%) under milnacip-
ran vs. 0 in the placebo group [RD +2% CI: −7%; +8%] (21). 
Similarly, Mease et al. compared milnacipran at 100 and 200 mg/
day with placebo in the treatment of fibromyalgia in 888 patients. 
The study was completed by 512 patients. Overall, adverse effects 
were reported in 188/224 patients (84%) in the milnacipran 
100 mg-group, 400/441 (90%) in the 200 mg-milnacipran group, 
and 190/223 patients (85%) in the placebo group [RD +1% CI: 
−6%; +8%] and [RD +6% CI: 0%; +12%]. Withdrawal due to 
adverse effects was necessary in 44/224 patients (20%) in the 
low-dose milnacipran group, in 119/441 patients (27%) in the 
high dose milnacipran group, and in 23/223 patients (10%) in 
the placebo group [RD +10% CI: 3%; +17%] and [RD +17% CI: 
+11%; +23%], respectively. Slow titration of dose and duration to 
mitigate these events was done in all cases. Main adverse effects 
were nausea, vomiting, dizziness and constipation, headache, 
tachycardia, palpitations, hot flush, dry mouth, and sweating 
(22). A multicentric 3-arm study by Clauw et  al. compared 
milnacipran at 100 and 200 mg/day with placebo in the treat-
ment of 1,207 patients with fibromyalgia. Adverse effects were 
reported in 358/399 patients (90%) in the 100 mg-milnaciprane 
group, 346/396 patients (87%) in the 200 mg-milnacipran group, 
and in 316/401 patients (79%) in the placebo group [RD +11% 
CI: +6%; +16%] and [RD +6% CI: +3%; +14%]. Withdrawal 
due to adverse effects was reported in 78/399 patients (20%), 
94/396 patients (24%), and 38/401 patients (9%) patients for the 
100 mg-, 200 mg-, and placebo group, respectively [RD +10% CI: 
+5%; +15%] and [RD +14% CI: +9%; +20%], respectively (23).
Venlafaxine
Ozyalcin et  al. compared venlafaxine at doses of 75 and 
150  mg/day with placebo in the treatment of migraine in 60 
patients. 49 completed the trial. Overall adverse effects were 
reported in 20/20 patients (100%) for the venlafaxine 75 mg/
day, in 20/21 patients (95%) for the venlafaxine 150  mg/day, 
and 10/19 patients (53%) for the placebo group [RD +47% CI: 
+17%; +70%] and [RD +43% CI: +12%; +66%], respectively. 
Withdrawal due to adverse effects was necessary in 3/20 patients 
(15%) for the venlafaxine 75 mg/day and 3/21 patients (14%) in 
the venlafaxine 150 mg/day group, but not in the placebo group 
[RD +15% CI: −9%; +39%] and [RD +14% CI: −9%; +37%]. 
The main adverse effects were nausea, vomiting, drowsiness, 
and insomnia (24). Yucel et al. compared venlafaxine at doses 
of 75 and 150  mg/day with placebo in the treatment of neu-
ropathic pain in 60 patients. 55 patients completed the trial. 
Overall adverse effects were reported in 9/20 patients (45%) for 
the 75 mg, in 14/20 patients (70%) for the 150 mg, and 11/20 
patients (55%) for the placebo group [RD +10% CI: −2%; +40%] 
and [RD +15% CI: −7%; +44%]. Withdrawal due to adverse 
effects was necessary in 1/20 patients (5%), 3/20 patients (15%), 
and 1/20 patients (5%) for the venlafaxine 75 mg/day, the ven-
lafaxine 150 mg/day, and the placebo group, respectively [RD 
0% CI: −2%; +22%] and [RD +10% CI: −15%; +34%]. Adverse 
effects were nausea, vomiting, dizziness, and somnolence (25). 
Forssell et al. compared venlafaxine at 37.5 mg 1–2×/day and 
placebo for the treatment of atypical facial pain in 30 patients 
in a double-blind crossover trial. Adverse effects occurred in 
18/30 patients (60%) in the venlafaxine group and in 18/30 
patients (60%) in the placebo group. Withdrawal due to adverse 
effects was necessary in 6/30 patients (20%) during treatment 
with venlafaxine and 2/30 patients (7%) under placebo [RD 
+13% CCI: −7%; +33%]. There was no difference regarding 
adverse effects between both groups (26).
Duloxetine
Chappell et  al. compared 60–120  mg/day duloxetine with pla-
cebo in the treatment of chronic pain due to osteoarthritis in 256 
patients. Only 111(87%) patients in the placebo and 93 (73%) 
in the duloxetine group completed the study. Patients treated 
with duloxetine had greater improvement in pain scores, but 
also showed more adverse effects than placebo-treated patients 
[64/128(50%) vs. 41/128(32%)] [RD +18% CI: +5%; +30%]. 
Withdrawal due to adverse effects was necessary in 24/128 
patients (19%) under duloxetine vs. 7/128 patients (5%) under 
placebo [RD +13%: +5%; +22%](27). Ho et  al. analyzed the 
potential of duloxetine to reduce morphine requirements after 
knee-replacement surgery in 50 patients. Patients received either 
duloxetine 60 mg/day or placebo. 47 patients were included in 
final analysis. Most common adverse effects in the duloxetine 
group were nausea and vomiting, followed by dizziness and head-
ache. Adverse effects were more common in the placebo group 
12/24 (50%) than in the duloxetine group 6/23 (26%) [RD +24% 
CI: −7%; +49%]. However, this comparison included all noted 
adverse effects irrespectively of their severity or mechanism. 
One patient of the duloxetine group died 6 months after surgery 
due to pneumonia. This death was not drug-related. Withdrawal 
due to adverse effects was not necessary in either group (28). 
In a study by Skljarevski et al., duloxetine at doses of 20, 60, or 
120 mg/day was compared to placebo in the treatment of chronic 
low-back pain in 404 patients of which 267 completed the trial. 
Discontinuation due to adverse effects was seen more frequently 
in the 120 mg duloxetine group (24.1% of the patients) compared 
to placebo (8.5%) (29). Similarly, another study by the same 
group compared duloxetine dosages ranging from 60 to 120 mg/
day with placebo in the treatment of chronic lower back pain. 
About twice as many patients discontinued because of adverse 
events in the duloxetine group (13.9%) than in the placebo group 
(5.8%). The most common reported adverse effects were nausea, 
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dry mouth, fatigue, diarrhea, sweating, dizziness, and constipa-
tion (30). In their third randomized placebo-controlled trial, 
Skljarevski et  al. analyzed 401 patients treated for CLBP with 
60  mg/day duloxetine or placebo. More patients discontinued 
due to adverse effects in the duloxetine group (15.2%) compared 
to the placebo group (5.4%). Overall adverse effects were more 
frequent in the duloxetine group. Most frequent adverse effects 
were nausea and dry mouth (31).
Mirtazapine
In in a double-blind crossover study in healthy subjects 30 mg/
day mirtazapine or placebo was administered. Adverse effects 
occurred in 9/10 patients (90%) under mirtazapine and in 2/10 
patients (20%) under placebo [RD +70% CI: +19%; +89%]. 
Reported adverse effects were dizziness, dry mouth, transient 
sedation, global weakness, unpleasant metallic taste, and swallow-
ing difficulty under treatment with mirtazapine (32). Bendtsen 
and Jensen analyzed mirtazapine in doses of 15–30 mg/day in a 
double-blind, placebo-controlled crossover study in 24 patients 
with tension-type headache. Overall, adverse effects were reported 
in 24 of 48 patients (50%) receiving mirtazapine compared to 18 
of 48 patients (38%) treated with placebo [RD +13% CI: −8%; 
+32%]. Withdrawal due to adverse effects was necessary in two 
patients during treatment with mirtazapine (4%), but none within 
the placebo group [RD +4% CI: −6%; +15%]. Main adverse effects 
were drowsiness, dizziness, weight gain, and dry mouth (33).
Fluoxetine
Atkinson et  al. compared desipramine, fluoxetine, and placebo 
for the treatment of chronic low-back pain in 121 patients. 
Overall adverse effects were reported in 16/31 patients (53%) 
for fluoxetine and 3/22 patients (14%) in the placebo group [RD 
+38% CI: +9%; +58%]. Withdrawal due to adverse effects was 
necessary in 3/43 patients (7%) under fluoxetine vs. 1/26 patients 
(4%) under placebo [RD +3% CI: −15%; +17%]. Adverse effects 
of fluoxetine were mainly sexual disturbances (19). A study by 
Rani et al. compared adverse effects of amitriptyline (25 mg/day), 
fluoxetine (20 mg/day), and placebo in 59 patients with chronic 
pain syndromes. Reported adverse effects occurred in 21 patients 
under fluoxetine and in 18 patients under placebo. Withdrawal 
due to adverse effects was not necessary in both groups. Reported 
adverse effects of fluoxetine were mainly nausea, dizziness, 
headache, palpitations, edema, gastritis, loss of appetite, and 
breathlessness (13).
adverse effects under Treatment with 
antidepressants: studies included Only 
in the systematic review
Studies that matched our inclusion criteria for review, but were not 
included in the meta-analyses due to absence of a placebo group 
comprised trials on amitryptiline, desipramine, and duloxetine.
Amitriptyline
Liu et  al. compared in the therapy of neuropathic pain ami-
triptyline with nortriptyline and an untreated control group. 
The study population included 228 patients. While no adverse 
effects and no withdrawals were reported in the control group, 
overall adverse effects occurred in 25/89 patients (28%) under 
amitriptyline and in 31/106 patients (29%) under nortriptyline. 
Withdrawal due to adverse effects was reported in 16/89 patients 
(18%) in the amitriptyline group vs. 13/106 patients (12%) under 
nortriptyline. The main side effect in both groups was sedation, 
followed by dizziness, drowsiness and dry mouth, and gain of 
body weight. There was no significant difference between both 
treatment groups in regard to adverse effects (34). Kalita et al. 
compared amitriptyline at escalating doses (12.5–50  mg/day) 
with pregabaline at escalating doses (75 mg 2×/day up to 300 mg 
2×/day) in the treatment of low-back pain in 200 patients. Similar 
rates of overall adverse effects for amitriptyline (18/103 patients, 
17%) and pregabaline (21/97 patients, 22%) were reported. Rates 
of withdrawal due to adverse effects were also similar (amitrip-
tyline 11/103 patients, 11% and pregabaline 12/97 patients, 
12%). Dry mouth and sedation were most frequently reported 
in the amitriptyline group (35). Magalhaes et al. compared the 
outcome of 72 patients with migraine treated with botulinum 
toxine type A (BTX) injections or systemic therapy with oral 
amitriptyline (25–50 mg/day). BTX injections were given once 
at defined points in the area of head and neck. Patients treated 
with amitriptyline showed higher incidences of constipation 
in 14/37 patients (38%) vs. 0/35 patients (0%), dry mouth in 
16/37 patients (43%) vs. 5/35 patients (14%), body weight gain 
in 16/37 patients (43%) vs. 4/35 patients (11%), and somnolence 
in 19/37 patients (51%) vs. 1/35 patients (3%) patients (36). Jose 
et al. compared amitriptyline (10–50 mg/day) with lamotrigine 
(50–200 mg/day) in 46 patients with diabetic neuropathy in a 
crossover study. In this study, 33/46 patients (72%) developed 
adverse effects under treatment with amitriptyline as opposed 
to 11/46 patients (24%) under treatment with lamotrigine. 
Furthermore, 19/46 patients (41%) had to be withdrawn due 
to adverse effects in the amitriptyline group vs. 8/46 patients 
(17%) patients in the lamotrigine group. Dizziness, constipation 
and dry mouth, somnolence, and increased sleep was reported 
for amitriptyline and hot flush as well as increased creatinine 
levels for lamotrigien as major adverse effects (37). Rintala et al. 
compared the 8-week treatment with amitriptyline (50 mg, 3×/
day), gabapentine (1,200  mg, 3×/day), and dip henhydramine 
(25 mg, 3×/day) in patients with neuropathic pain induced by 
spinal cord injuries in a crossover study design with 210 patients. 
Adverse effects were reported in 67/210 patients (32%) under 
treatment with amitriptyline, in 57/201 patients (28%) under 
treatment with gabapentine, and 43/205 patients (21%) patients 
under treatment with diphenhydramine as active control group. 
Main adverse effects of amitriptyline were drowsiness, consti-
pation, dry mouth, dizziness, nausea, palpitations, and weight 
gain (38).
Desipramine
Walker et al. compared desipramine at 75 mg/day and fluoxetine 
at 20 mg/day in the treatment of chronic tension-type headache 
in 37 patients. The study was completed by 25 out of 37 patients. 
Adverse effects occurred in 6/19 patients (32%) of the desip-
ramine group and 6/18 patients (33%) in the fluoxetine group. 
Withdrawal due to adverse effects was necessary in 4/19 patients 
TaBle 2 | Risk ratio (RR) and corresponding 95%-confidence interval (CI) for 
overall adverse effects and withdrawal due to adverse effects.
effect Medication estimated 
rr
95%-ci strength of 
evidence
Withdrawal due to 
adverse effects
Amitriptyline 4.09 1.31; 12.82 ++
Nortriptyline 0.81 0.12; 5.44 +−
Desipramine 6.31 1.20; 33.14 ++
Milnacipran 2.28 1.87; 2.77 ++
Venlafaxine 3.10 1.15; 8.35 ++
Duloxetine 2.47 1.82; 3.36 ++
Mirtazapine 5 0.25; 98.86 +
Fluoxetine 1.81 0.2; 16.54 +
Overall adverse 
effects
Amitriptyline 2.9 0.67; 12.58 +
Nortriptyline 1.5 0.17; 12.99 +
Desipramine 3.77 1.33; 10.68 ++
Milnacipran 1.06 1.00; 1.13 0
Venlafaxine 1.44 1.03; 2.2 ++
Duloxetine 1.17 1.06; 1.30 ++
Mirtazapine 2.05 0.54; 7.82 +
Fluoxetine 3.78 1.25; 11.43 ++
Interpretation of RRs and 95%-CIs are shown as evidence: ++, strong evidence; +, 
intermediate evidence; +−, inconclusive results; 0, evidence of absence of a clinically 
relevant effect in either direction (limits for clinical relevance defined as 0.8 < RR < 1.2).
Strong evidence + statistical significance for AE/WDR for AD in “bold.”
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(21%) under desipramine vs. 6/18 patients (33%) under fluox-
etine. Reasons for withdrawal were drowsiness, fatigue, excessive 
sleepiness, malaise, nausea, weakness, faintness, insomnia, and 
headache. Patients taking fluoxetine discontinued the study 
medication for nausea, vomiting, and malaise (39).
Duloxetine
Leombruni et  al. reported data of a comparative trial with 
60 mg/day duloxetine and 1,500 mg/day l-carnitine in 65 female 
patients with FM of which 51/65 patients (78.5%) completed 
the trial. Both treatments led to improvement in pain and 
depression, but there were significant more adverse effects in 
the duloxetine group [8/29 (27%) patients vs. 0/22 patients] 
compared with the l-carnitine group. Reported adverse effects 
under duloxetine were nausea, anxiety, insomnia, and diarrhea. 
Out of 14 dropouts, 8 were due to duloxetine-related adverse 
effects (40). Giannantoni et  al. compared additional therapy 
with 60 mg/day duloxetine +  standard treatment with 0.4 mg/
day tamsulosin + 320 mg/day palmetto and standard multidrug 
regimen with 0.4 mg/day tamsulosin + 320 mg/day palmetto in 
38 patients with chronic pelvic pain syndrome. Withdrawal due 
to adverse effects was more frequent (4/19 patients, 20%) in the 
duloxetine group compared to the standard treatment with (0/19 
patients, 0%) (41). Mazza et al. compared 60 mg/day duloxetine 
with 20  mg/day escitalopram in the treatment of CLBP in 85 
patients of which 80 completed the study. Adverse effects were 
similar in both groups (15/41 patients, 36% under duloxetine vs. 
14/39 patients, 36%) under escitalopram. Adverse effect-related 
treatment discontinuation was not necessary in both groups (42).
Meta-analysis
Overall, 60 different adverse effects under therapy with antide-
pressants were reported in the studies included in the review and/
or the meta-analyses. Reported side effects are listed in Table S2 in 
Supplementary Material. Meta-analyses revealed higher risks for 
overall adverse effects and side effect-related withdrawals under 
treatment with antidepressants compared to placebo. Specific 
adverse effects occurring under treatment with antidepressants 
of either subgroup were identified.
RRs and RDs for Overall Adverse Effects
Among TCAs, the RRs for overall adverse effects were 2.9 
(95%-CI [0.67; 12.58]) under treatment with amitriptyline, 1.50 
(95%-CI [0.17; 12.99]) under nortriptyline, and 3.77(95%-CI 
[1.33; 10.68]) under desipramine. Milacipran revealed a RR of 
1.06 (95%-CI [1.00; 1.13]) for overall adverse effects while overall 
adverse effects under treatment with venlafaxine had a RR of 1.44 
(95%-CI [1.03; 2.02]) and 1.17 (95%-CI [1.06; 1.30]) under treat-
ment with duloxetine. The reported RR for overall adverse effects 
under treatment with mirtazapine was 2.05 (95%-CI [0.54; 7.82]). 
Fluoxetine showed a RR of 3.78 (95%-CI [1.25; 11.43]) for overall 
adverse effects. Details are shown in Table 2 and Figures 2A–G. 
Comparative analysis of RDs for overall adverse effects of each 
drug showed that the placebo-adjusted risk to develop either side 
effect was highest under treatment with amitriptyline, mirtazap-
ine, and fluoxetine. The lowest risk was under treatment with 
duloxetine and milnacipran (Figure 3).
Evidence for Withdrawals Related to Adverse Effects
Withdrawal due to adverse effects had a RR of 4.09 (95%-CI 
[1.31; 12.82]) under treatment with amitriptyline, 0.81(95%-
CI [0.12; 5.44]) under treatment with nortriptyline, and 6.31 
(95%-CI [1.20; 33.14]) under treatment with desipramine. The 
RR for treatment discontinuation due to adverse effects was 2.28 
(95%-CI [1.87; 2.77]) for milnacipran, 3.10 (95%-CI [1.15; 8.35]) 
for venlafaxine, and 2.47 (95%-CI [1.82; 3.36]) for duloxetine. 
The reported RR for side effect-related withdrawal was 5 (95%-CI 
[0.25; 98.86]) for mirtazapine and 1.81 (95%-CI [0.2; 16.54]) for 
fluoxetine. Details are shown in Figures 4A–F.
Comparing RDs for side effect-related withdrawals shows the 
highest RD for desipramine, followed by duloxetine, venlafaxine, 
and milnaciprane. The lowest RD was seen in the nortriptyline 
group as shown in Figure 5.
Evidence for Specific Adverse Effects of Each 
Analyzed Antidepressant
Amitryptiline
Adverse effects with strong evidence (+++/++) of amitripty-
line were dry mouth (RR 3.14; 95%-CI [1.10; 8.94]), headache 
(RR 3.39; 95%-CI [0.92; 12.55]), thirst (RR 18.95; 95%-CI [1.19; 
301.39]), body weight gain (RR 8.74; 95%-CI [1.12; 68.32]), and 
constipation (RR 1.60; 95%-CI [1.19; 2.15]). Adverse effects 
with inconclusive evidence (±) of amitriptyline were gastritis, 
sweating, and dizziness under amitriptyline, headache and 
somnolence under nortriptyline. Adverse effects occurring 
more often in placebo groups (−−/−) of amitriptyline were 
insomnia and itching (strong evidence) and nausea, vomit-
ing, urinating difficulties and abdominal pain (intermediate 
evidence).
FigUre 2 | Continued
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Nortriptyline
Adverse effects with strong evidence (+++/++) of nortriptyline 
were constipation (RR 1.84; 95%-CI [0.90; 3.74]), drowsiness (RR 
3.94; 95%-CI [2.14; 7.28]), and insomnia (RR 1.40; 95%-CI [0.92; 
2.13]). Adverse effects with weak evidence (+) of nortriptyline 
were dizziness, dry mouth, heart burn, orthostatic hypotension, 
increased appetite, nervousness, palpitations, sedation, sweat-
ing, weight gain, and abdominal pain. Blurred vision is the only 
side effect occurring more frequently under placebo than under 
nortriptyline with intermediate evidence.
FigUre 3 | Comparative analysis for the placebo effect-adjusted risk of the overall adverse effects of the different analyzed antidepressants. Risk differences were 
used for placebo effect-adjusted risk.
FigUre 2 | Meta-analyses of overall adverse effects under treatment with different antidepressants. RR = risk ratio; 95%-CI = 95% confidence interval; 
PI = prediction interval. Overall adverse effects under treatment with amitriptyline (a), with nortriptyline (B), with desipramine (c), with milnacipran  
(D), with venlafaxine (e), with duloxetine (F), and with mirtazapine (g).
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Desipramine
The side effect with strongest evidence (+++/++) under treat-
ment with desipramine was dry mouth (RR 5.12; 95%-CI [1.41; 
18.57]). Adverse effects with weak evidence (+) of desipramine 
were constipation, dizziness, drowsiness, headache, insomnia, 
loss of libido, nausea, shaking, sweating, and vomiting.
Milnacipran
Adverse effects with strong evidence (+++/++) under anal-
gesic treatment with milnacipran were constipation (RR 4.52; 
95%-CI [3.29; 6.20]), dizziness (RR 1.94; 95%-CI [1.46; 2.58]), 
dry mouth (RR 2.40; 95%-CI [1.27; 4.53]), headache (RR 1.62; 
95%-CI [1.23; 2.12]), hot flush (RR 6.17; 95%-CI [3.42; 11.13]), 
hypertension (RR 3.31; 95%-CI [1.74; 6.28]), insomnia (RR 
1.49; 95%-CI [0.98; 2.27]), nausea (RR 1.82; 95%-CI [1.60; 
2.08]), palpitations (RR 3.46; 95%-CI [2.16; 5.53]), sweating 
(RR 4.97; 95%-CI [2.58; 9.57]), tachycardia (RR 5.56; 95%-CI 
[1.94; 15.94]), and vomiting (RR 2.77; 95%-CI [1.80; 4.26]). 
Adverse effects with inconclusive evidence (±) of milnacarpine 
were respiratory infections. Adverse effects occurring more 
often in placebo groups (−−/−) under placebo were diarrhea 
(strong evidence), edema, and nasopharyngitis (intermediate 
evidence).
Venlafaxine
Adverse effects with strong evidence (+++/++) of venlafaxine 
were drowsiness (RR 2.51; 95%-CI [0.86; 7.28]), somnolence (RR 
7.39; 95%-CI [0.97; 56.50]), and vomiting (RR 16.07; 95%-CI 
[3.18; 81.29]). Adverse effects with weak evidence (+) of ven-
lafaxine were constipation, jaw spasm, loss of libido, mydriasis, 
FigUre 4 | Continued
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nausea, nightmares, sedation, sweating, urinating difficulty, 
headache, and fatigue. Adverse effects with inconclusive evidence 
(±) of venlafaxine were dizziness, dry mouth, loss of appetite, and 
palpitations.
Duloxetine
Adverse effects with strong evidence (+++/++) under dulox-
etine were constipation 4.02 (95%-CI [1.57; 10.33]), dry mouth 
2.95 (95%-CI [1.17; 7.43]), hyperhidrosis 13.33 (95%-CI [1.76; 
101.14]), and nausea 4.11 (95%-CI [1.15; 14.70]). Adverse effects 
with weak evidence (+) of duloxetine were dizziness, dyspnoe, 
hypertensive encephalopathy, muscular weakness, myocardial 
infarction, osteoarthritis, pruritus, and somnolence. Adverse 
effect with inconclusive evidence (±) of duloxetine was diarrhea. 
Adverse effects occurring more often in placebo groups (−−/−) 
under placebo were chest pain, headache, and vertigo.
FigUre 5 | Comparative analysis of the placebo effect-adjusted risk for adverse effect-related withdrawal of the different analyzed antidepressants. Risk differences 
were used for placebo effect-adjusted risk.
FigUre 4 | Meta-analyses of side effect-related withdrawal under treatment with different antidepressants. RR = risk ratio; 95%-CI = 95%-confidence interval; 
PI = prediction interval. Adverse effect-related withdrawal under treatment with amitriptyline (a), with nortriptyline (B), with desiparmine (c), with milnacipran  
(D), with venlafaxine (e), and with duloxetine (F).
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Mirtazapine
Adverse effects with strong evidence (+++/++) under duloxetine 
were dizziness (RR 3.61; 95%-CI [0.96; 13.56]), drowsiness (RR 
1.56; 95%-CI [0.84; 2.88]), and sedation (RR 3.5; 95%-CI [0.95; 
12.9]). Adverse effects of weak evidence (+) under analgesic 
treatment with milnacipran were mostly arthralgia, fall, and 
fatigue. Adverse effects with weak evidence (+) for mirtazapine 
were concentration disturbances, dry mouth, edema, global 
weakness, metallic taste, swallowing difficulty, and weight gain. 
Under duloxetine remains unclear. Adverse effect with weak 
evidence (+) of mirtazapine was nausea under mirtazapine. 
Adverse effects occurring more often in placebo groups (−−/−) 
under placebo were fainting, irritability, increased appetite, and 
sleep disturbances (intermediate evidence).
Fluoextine
Fluoxetine showed adverse effects with strong evidence 
(Table 3). Adverse effects with weak evidence (+) of fluoxetine 
were breathlessness, dizziness, edema, headache, loss of appetite, 
loss of libido, nausea, and palpitations. Dry mouth was the only 
adverse effect that occurred more often under placebo than under 
fluoxetine (−−/−).
Risks for specific adverse effects under treatment with the 
analyzed antidepressants are detailed in Table 3.
TaBle 3 | Risk for specific adverse effects under treatment with the analyzed 
antidepressants.
Drug 
(prediction 
interval)
side effect risk 
ratio
95%-ci evidence
amitriptyline Dry mouth 3.14 1.10; 8.94 ++
headache 3.39 0.92; 12.55 ++
Body weight gain 8.74 1.12; 68.32 ++
Thirst 18.95 1.19; 301.39 ++
constipation 1.60 1.19; 2.15 ++
Edema 1.8 0.18; 18.21 +
Drowsiness 1.60 0.52; 4.91 +
Irritability 8.19 0.45; 147.47 +
Palpitations 1.55 0.29; 8.24 +
Blurred vision 6.37 0.34; 119.6 +
Diarrhea 1.21 0.29; 5.09 +
Gastritis 0.9 0.31; 2.61 +−
Sweating 1.14 0.33; 3.94 +−
Dizziness 1.12 0.47; 2.66 +−
Nausea 0.54 0.21; 1.38 −
Vomiting 0.09 0; 1.59 −
Abdominal pain 0.14 0.01; 2.68 −
Urinating difficulty 0.40 0.04; 4.09 −
insomnia 0.12 0.02; 0.94 −−
itching 0.42 0.16; 1.07 −−
nortriptyline Drowsiness 3.94 2.14; 7.28 ++
constipation 1.84 0.90; 3.74 ++
insomnia 1.40 0.92; 2.13 ++
Dizziness 2.90 0.32; 26.10 +
Dry mouth 2.04 0.75; 5.59 +
Heart burn 3 0.14; 62.49 +
Increase in appetite 2.78 0.11; 67.49 +
Nervousness 2.78 0.11; 0.67 +
Orthostatic hypotension 1.26 0.78; 2.03 +
Palpitations 1.55 0.28; 8.61 +
Sedation 1.26 0.78; 2.03 +
Sweating 1.40 0.62; 3.15 +
Weight gain 2.90 0.32; 26.10 +
Abdominal pain 2.78 0.11; 67.49 +
Somnolence 1 0.08; 13.02 +−
Headache 1 0.08; 13.02 +−
Blurred vision 0.33 0.02; 6.94 −
Desipramine Dry mouth 5.12 1.41; 18.57 ++
Constipation 5.78 0.74; 44.97 +
Dizziness 3 0.13; 66.8 +
Drowsiness 11 0.68; 178.53 +
Headache 5 0.27; 93.96 +
Insomnia 5 0.27; 93.96 +
Loss of libido 2.21 0.09; 51.85 +
Nausea 5 0.27; 93.96 +
Shaking 5 0.27; 93.96 +
Sweating 7 0.4; 121.94 +
Vomiting 3 0.13; 66.8 +
Milnacipran
2.26; 9.04 constipation 4.52 3.29; 6.20 +++
1.37; 5.57 Vomiting 2.77 1.80; 4.26 +++
1.04; 3.62 Dizziness 1.94 1.46; 2.58 +++
1.47; 2.25 nausea 1.82 1.60; 2.08 +++
1.04; 2.50 headache 1.62 1.23; 2.12 +++
1.09; 10.98 Palpitations 3.46 2.16; 5.53 +++
Dry mouth 2.40 1.27; 4.53 ++
hot flush 6.17 3.42; 11.13 ++
hypertension 3.31 1.74; 6.28 ++
insomnia 1.49 0.98; 2.27 ++
TaBle 3 | Continued
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Drug 
(prediction 
interval)
side effect risk 
ratio
95%-ci evidence
sweating 4.97 2.58; 9.57 ++
Tachycardia 5.56 1.94; 15.94 ++
Arthralgia 1.5 0.16; 14.06 +
Fall 4.52 0.25; 82.36 +
Fatigue 2 0.23; 17.43 +
Respiratory infections 1.07 0.71; 1.62 +−
Edema 0.33 0.06; 1.93 −
Nasopharyngitis 0.73 0.48; 1.12 −
Diarrhea 0.68 0.42; 1.11 −−
Venlafaxine Vomiting 16.07 3.18; 81.29 ++
somnolence 7.39 0.97; 56.50 ++
Drowsiness 2.51 0.86; 7.28 ++
Constipation 1.76 0.51; 6.03 +
Jaw spasm 4.39 0.52; 36.98 +
Loss of libido 4.39 0.52; 36.98 +
Mydriasis 3.64 0.42; 31.56 +
Nausea 3.13 0.74; 13.85 +
Nightmares 1.22 0.68; 2.21 +
Sedation 6.35 0.35; 115.28 +
Sweating 1.98 0.18; 21.37 +
Urinating difficulty 1.5 0.67; 3.34 +
Headache 1.06 0.95; 1.18 0
Fatigue 1.06 0.95; 1.18 0
Dizziness 0.93 0.25; 3.45 +−
Dry mouth 1.04 0.66; 1.64 +−
Palpitations 1.08 0.74; 1.57 +−
Loss of appetite 1.08 0.79; 1.47 +−
Duloxetine constipation 4.02 1.57; 10.33 ++
Dry mouth 2.95 1.17; 7.43 ++
hyperhidrosis 13.33 1.76; 101.14 ++
nausea 4.11 1.15; 14.70 ++
Dizziness 2.72 0.77; 9.57 +
Dyspnoe 3.03 0.12; 73.52 +
Hypertensive 
encephalopathy
3.16 0.13; 76.69 +
Muscular weakness 3.03 0.12; 73.52 +
Myocardial infarction 1.52 0.24; 9.61 +
Osteoarthritis 3.16 0.13; 76.69 +
Pruritus 3.13 0.13; 73 +
Somolence 2.47 0.24; 25.39 +
TIA 3.22 0.34; 30.70 +
Wrist fracture 3.16 0.13; 76.69 +
Diarrhea 1.19 0.42; 3.37 +−
Headache 0.73 0.20; 2.59 −
Vertigo 0.70 0.14; 3.47 −
Chest pain 0.70 0.12; 4.02 −
Mirtazapine Dizziness 3.61 0.96; 13.56 ++
Drowsiness 1.56 0.84; 2.88 ++
sedation 3.5 0.95; 12.9 ++
Concentration 
disturbances
2 0.19; 20.61 +
Dry mouth 1.85 0.43; 7.94 +
Edema 1.5 0.27; 8.19 +
Global weakness 3 0.14; 65.55 +
Metallic taste 3 0.14; 65.55 +
Swallowing difficulty 3 0.14; 65.55 +
Weight gain 6 0.78; 46.14 +
Nausea 1 0.15; 6.53 +−
Sleep disturbances 0.67 0.12; 3.64 −
Irritability 0.2 0.03;1.59 −
Drug 
(prediction 
interval)
side effect risk 
ratio
95%-ci evidence
Increased appetite 0.6 0.16; 2.23 −
Fainting 0.33 0.02; 7.28 −
Fluoxetine Breathlessness 2.58 0.11; 59.62
Dizziness 1.71 0.17; 17.38 +
Edema 1.71 0.17; 17.38 +
Headache 1.29 0.24; 6.86
Loss of appetite 2.58 0.11; 59.62
Loss of libido 10.71 0.64; 178.16
Nausea 1.42 0.4; 5.17
Palpitations 2.58 0.11; 59.62
Gastritis 1.2 0.46; 3.13 +−
Dry mouth 0.35 0.03; 3.67 −
Evidence is estimated according to risk ratios and corresponding 95%-CI obtained 
from meta-analyses.
+++/++, strong evidence for side effect under treatment; +, weak evidence for side 
effect under treatment; +−, inconclusive evidence; −, weak evidence for placebo-
induced side effect; −−, strong evidence for placebo-induced side effect; RR, risk ratio; 
95%-CI, 95%-confidence interval; PI, prediction interval.
Symptoms in “bold” show statistical significance + strong evidence, underlined symp-
toms are more often under placebo than under therapy, and evidence remains unclear 
for symptoms in “italic.”
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Comparative Analysis of RDs of Each Drug for the 
Most Common Adverse Effects
Risk differences for each adverse effect are illustrated in 
(Figures  6A–H). Regarding all analyzed drugs in this meta-
analysis the most common adverse effects were dry mouth, 
dizziness, followed by nausea, headache, constipation, sweating/
hyperhidrosis, drowsiness, and palpitations.
Comparative analyses of placebo-adjusted RDs revealed the high-
est risk to develop “dry mouth” for desipramine, amitriptyline, nor-
triptyline, and mirtazapine (Figure S1 in Supplementary Material), 
while the highest risk for dizziness was seen under mirtazapine 
(Figure S1B in Supplementary Material). Risk of nausea occurred was 
highest under venlafaxine, duloxetine, and milnacipran, and was low 
under amitriptyline (Figure S1C in Supplementary Material). Risk of 
headache was higher under treatment with amitriptyline and desip-
ramine, while risk of constipation was almost equal for TCAs and 
SSRIs (Figures S1C,D in Supplementary Material). Risk of drowsiness 
was most severe under therapy with despramine and nortriptyline, 
followed by amitriptyline, mirtazapine, and venlafaxine. Risk of 
hyperhidrosis was most pronounced under desipramine, duloxetine, 
and milnacipran. Risk of palpitations was highest under amitriptyline 
and milnacipran (Figures S1F–H in Supplementary Material).
DiscUssiOn
The major findings of our analyses are (1) all antidepressants 
included in the analysis, except nortriptyline, showed higher 
incidence of adverse effects compared to placebo, (2) amitrip-
tyline, mirtazapine, desipramine, venlafaxine, fluoxetine, and 
nortriptyline showed the highest placebo effect-adjusted risk 
of adverse effects, (3) risk for withdrawal due to side effects was 
highest in desipramine, milnacipran, venlafaxine, and duloxetine, 
(4) the most frequent adverse effects under treatment with anti-
depressants were dry mouth, dizziness, nausea, headache, and 
constipation followed by palpitations, sweating, and drowsiness, 
and (5) antidepressants showed specific adverse effect profiles. 
Taken together, our synthesized data confirm previous studies 
demonstrating safety of antidepressants in the treatment of 
chronic pain and further advance these results. Distinct profiles 
of adverse effects identified in this analysis might provide useful 
information for personalized multimodal treatment which takes 
both comorbidities and co-medication into consideration.
Adverse effects due to antidepressive treatment have heteroge-
neous mechanisms of action. TCAs, for example, block histaminic, 
cholinergic, and alpha1-adrenergic receptor sites, resulting in 
occurrence of adverse effects, including weight gain, dry mouth, 
constipation, drowsiness, and dizziness (43). Monoamine oxidase 
inhibitors show an interaction with tyramine which can lead to 
severe arterial hypertension and furthermore show interactions 
with numerous drugs. The newer generation of antidepressants, 
SSRIs are single-receptor selective drugs which target one specific 
brain receptor site without agonizing unwanted receptor sites or 
transmitters, such as histamine and acetylcholine. Importantly, 
in the majority of cases those adverse effects usually appear with 
initiation of treatment while therapeutic benefits may be delayed. 
However, in our analyses, differences in the delay of onset of 
analgetic action may reduce comparibility of studies, particularly 
those with shorter durations of observation.
TCA is the first group of antidepressants used in the treatment 
of pain with decades of clinical experience. Treatment costs are 
comparably low (43). Previous prospective studies in patients 
with chronic pain highlighted adverse effects, such as blurred 
vision, urinary retention, constipation, and dry mouth, as well as 
antihistaminic adverse effects, such as weight gain and sedation. 
Our synthesized analysis not only confirmed strong evidence 
for dry mouth, thirst, constipation, headache, and gain in body 
weight but also blurred vision and palpitations. Adjusting results 
for potential placebo effects seems to be particularly relevant as 
insomnia and itching occurred as important side effect under 
placebo as well as nausea, vomiting, abdominal pain, and urinat-
ing difficulty. In placebo-controlled studies of amitriptyline, our 
synthesized analyses also showed a significant placebo related 
risk for these adverse effects observed might point to a specific 
protective effect of amitriptyline or might be explained by the 
complex underlying pathophysiology of chronic pain forms.
Similar to our results, Finnerup et al. reported somnolence, 
constipation, and dry mouth as major adverse effects for TCA 
in a recent review and meta-analysis of studies of neuropathic 
pain management (44). As opposed to studies of TCA in patients 
with depression, severe adverse effects related to hypotension or 
prolonged QT intervals were not evident in our analyses (45). 
This might be due to the fact that lower doses were necessary in 
analgesic treatment compared to those doses that are needed for 
treatment for depression. More recently designed antidepressants 
such as SSNRI were suggested to cause fewer adverse effects than 
TCA while yielding similar efficacy in the treatment of depression 
(46). The mechanism of action of SSNRI is a dual inhibition of 
5HT and NE reuptake. However, selectivitiy and intenstity of 
inhibition differ among SSNRIS, probably explaining diffrences 
in the adverse effect profiles. Duloxetine and venlafaxine are 
more selective for serotonin reuptake inhibition at lower doses 
TaBle 3 | Continued
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compared to milnacipran. Milnacipran shows higher selectivity 
for norepinephrine compared to duloxetine and venlafaxine 
(21–32). Adverse effects occurring with highest evidence under 
treatment with venlafaxine are vomiting, somnolence, and drowsi-
ness. RD added nausea and constipation as important adverse 
effects. Neither palpitations nor hypertension was observed. 
This might be related to the fact that venlafaxine was applied in 
sub-antidepressive doses, where the threshold for noradrenergic 
adverse effects might not have been reached. However, in an 
experimental setting, venlafaxine led to complex disturbances 
FigUre 6 | Comparative analyses of adverse effects of each analyzed drug using risk differences. (a) Amitriptyline, (B) nortriptyline, (c) desipramine, (D) duloxetine, 
(e) venlafaxine, (F) milnacipran, (g) mirtazapine, (h) fluoxetine.
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of the autonomic nervous system in a dose-dependent fashion 
even in the lower doses, possibly indicating a continuous 
dose-dependent rather than a threshold-based all or nothing 
mechanism of noradrenergic adverse effects (47, 48). Cognitive 
functions were not altered in the same expiremental setting, 
consistent with a predominant effect on centers of autonomic 
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sympathetic control and efferent adrenergic pathways (49). Even 
though acting in a similar fashion, different adverse effects were 
observed for duloxetine. Our synthesized analyses revealed that 
constipation, dry mouth, hyperhidrosis, and nausea are adverse 
effects of venlafaxine with strong evidence. Compared to a previ-
ous analysis that has identified only nausea as adverse effect with 
the same level of evidence, our analyses suggest a less favorable 
side effect profile of venlafaxine (44). In fact, our analyses indicate 
that, among assessed antidepressants, milnacipran shows the 
highest degree of evidence for several specific adverse effects 
including constipation, vomiting, dizziness, nausea, headache 
and palpitations, dry mouth, hot flush, hypertension, insomnia, 
sweating, and tachycardia. However, using RD for placebo-
adjusted risks, only constipation, nausea, hot flush, palpitations, 
tachycardia, and vomiting emerged as high risk adverse effects. 
Interestingly, our analyses showed that diarrhea occurred less 
often under milnacipran compared to placebo. As constipation 
is a side effect occurring with strong evidence under milnacip-
ran, a protective effect of milnacipran against diarrhea appears 
plausible. This might be relevant to the treatment of patients with 
chronic pain and gastroenterologic comorbidities.
Our meta-analysis revealed that under treatment with 
mirtazapine dizziness, drowsiness, and sedation are important 
adverse effects. However, RD that adjusted adverse effects for pla-
cebo identified sedation, weight gain, dizziness, drowsiness, dry 
mouth, and concentration disturbances as main adverse effects, 
possibly indicating a stronger clinically relevant anticholonergic 
component to the underlying mechanism of action. Consistently, 
irritability, increased appetite and fainting occurred less often 
under treatment with mirtazapine compared to placebo, possibly 
due to a protective effect of the drug.
While adverse effects such as gastrointestinal symptoms, 
nausea, vomiting, diarrhea, and sexual dysfunction are frequently 
reported under treatment with fluoxetine for depression, the 
present analysis of fluoxetine revealed no adverse effect occur-
ring with strong evidence (50, 51). However, RD-based analyses 
showed nausea and palpitations to occur with high evidence. This 
profile is consistent with the absence of any anticholinergic action 
and confirms previous research indicating a beneficial adverse 
effect profile of SSRI compared to TCA (46). However, SSRI are 
less effective for analgesic treatment which might be due to a 
significant noradrenergic component to the mechanism whereby 
antidepressants alleviate pain.
The highest evidence for overall adverse effects was seen 
under treatment with desipramine, venlafaxine, and fluoxetine 
by analyzing RRs However, the drugs most likely leading to dis-
continuation of the medication were desipramine, milnacipran, 
venlafaxine, and duloxetine possibly indicating that severity and 
unpleasant perception of adverse effects was more pronounced 
under treatment with these antidepressants compared to, e.g., the 
SSRI fluoxetine and milnacarpine.
Overall, adverse effect rate under treatment with placebo 
was relatively high possibly reflecting increased awareness and 
expectancy of adverse effects in patients with chronic pain. The 
induction or the worsening of symptoms induced by placebo 
administration also referred to as “nocebo effect” might par-
ticularly be relevant in those patients that suffer from long-term 
illness with unpleasant symptoms such as chronic pain. It is 
important to point out that, compared to other analgesic drugs, 
adverse effects of antidepressants have been shown reversible and 
not linked to any structural organ damage (52).
There are recommendations for symptomatic treatment of 
underlying specific diseases of chronic pain. Some recommenda-
tions are approved by the FDA, but often individual treatment 
regimens and off-label use are applied. Fibromyalgia syndrome 
is defined as diffuse pain for more than 3  months and at least 
11 out of 18 defined tender points by the American College 
of Rhematology, fatigue, sleep disturbances, depression, and 
cognitive dysfunction (53). The mechanism of pain is unclear, 
but one explanation might be the enhanced central sensitization. 
In addition, psychological factors, such as depression, anxiety, 
and stress, contribute to chronification of pain in these patients. 
Besides non-pharmacological treatments, TCA and SSRI are 
recommended. It has been shown that treatment with fluoxetine 
is less effective than TCA in the treatment of fibromyalgia related 
chronic pain. However, the clinical decision on whether selecting 
a TCA or SSRI for pain treatment in these patients should also 
take into account specific profiles of adverse effects. Patients with 
fibromyalgia suffer frequently from limited functional status (54). 
This symptom might be further deteriorated by drowsiness, an 
adverse effect for which our analysis showed the highest risk in 
despramine and nortriptyline. Duloxetine and milnacipran are 
also approved by the FDA for treatment of fibromyalgia (55–57).
Neuropathic pain occurs in up to 50% of patients with periph-
eral neuropathy (58). The major etiology for neuropathic pain 
is diabetic neuropathy. 21% of patients suffering from diabetes 
mellitus type 2 more than 10 years develop diabetic neuropathy. 
Effectiveness in treatment of diabetic neuropathy has been shown 
for TCAs as amitriptyline, clomipramine, and imipramine as well 
as for SSRIs as fluoxetine, citalopram, and paroxetine. However, 
most studies show higher effectiveness for TCAs—amitriptyline, 
nortriptyline, desipramine, and imipramine—compared to SSRIs 
paroxetine and fluoxetine (59–62). Duloxetine was approved by 
FDA for the treatment of diabetic neuropathy at doses of 60 mg/
day. Even though not approved, venlafaxine has shown positive 
effects in off-label use at doses of 150–225 mg/day. Patients with 
diabetic neuropathic frequently suffer from complex disturbances 
of the autonomic nervous system with cardiovascular, gastroen-
terologic and urogenital, and other symptoms which is why an 
accurate matching between risk for adverse effects of the selected 
antidepressant and manifest autonomic symptoms appears 
beneficial (63). For instance, nausea is a prevalent symptom of 
diabetic neuropathy which showed highest risk of occurrence in 
our analysis under treatement with amitriptyline (64). While this 
does not prove a clinically relevant additive effect of TCA treat-
ment and neuropathy in the development of nausea, knowledge 
of this observation might prove useful in the multimodal treat-
ment of diabetic neuropathy.
Postherpetic neuralgia results after infection with varicella 
zoster virus, a neurotropic virus that can remain hidden in 
ganglion of sensory cranial nerves and can be reactivated as 
late onset even years after infection as acute herpes zoster (65). 
Postherpetic neuralgia is a ususally drug resistant pain that 
lasts longer than 3  months in the skin area formerly affected 
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by herpes zoster (66–68). Current guidelines recommend 
therapy with TCA, tramadol or opioids while TCA and alpha2 
ligands are the most common drugs (69). Effectiveness has 
been shown for treatment with TCA—namely amitriptyline, 
desipramine, and nortriptyline, as well as for treatment with 
SSRI as fluoxetine. Since pain is usually severe and can last for 
years, causing physical and social disability focus of treatment 
should be predominantly driven by efficacy in pain reduction 
(70). However, adverse effects should be anticipated, which 
might be particularly relevant when headache is induced by the 
drug, an adverse effect which showed highest risk under treat-
ment with amitriptyline in our analysis. Chronic low-back pain 
is backache that lasts for at least 3 months often associated with 
radiculopathy or lumbar canal stenosis (71, 72) and is persistent 
in up to 45% of affected patients. Assumed pathophysiological 
mechanisms include changes of the central nervous system 
with neuronal hyperactivity, membrane excitability, and con-
sequent dysfunction of inhibitory systems. Short-term efficacy 
of NSAIDs and opioids has been shown, but chronic pain is 
commonly treated by antidepressants (73). TCA are effective in 
alleviating chronic low-back pain but show significant adverse 
effects (74, 75). SNRIs show lower efficacy and less adverse 
effects in the treatment of chronic low-back pain (76–78). 
Duloxetine is activating descending inhibitory pathways in the 
brain stem and the spinal cord which might explain its efficacy 
in the treatment of chronic low-back pain (29). While efficacy in 
pain reduction is the primary goal of treatment, complex effects 
of chronic low-back pain on biologic, psychologic, and social 
aspects need to be considered when selecting an antidepressive 
treatment as part of multimodal therapy (79). Adverse effects 
such as dizziness and drowsiness, which showed highest risk 
under mirtazapine; despramine and nortriptyline, respectively, 
in our analysis, might further contribute to already impaired 
functional status and increased risk of falls in elder patients with 
chronic low-back pain (80). This might be similarly relevant to 
patients with osteoarthritis induced chronic pain which is also 
more prevalent in the elderly (81).
Standard treatment for chronic tension-type headache is 
amitriptyline (82). Amitriptyline is the only drug with prophy-
lactic effect, but the mechanism is unknown. SSRI have no or 
limited analgesic effect and it has been shown that SSRI are no 
more effective than placebo. Venlafaxine is efficacious for chronic 
tension-type headache. Efficacy of mirtazapine has been shown 
to be comparable to amitriptyline. Recommended treatments for 
chronic tension-type headache are amitriptyline, clomipramine, 
maprotiline and mirtazapine while migraine should be treated 
by amitriptyline, fluoxetine and venlafaxine. While our analysis 
showed that among antidepressants risk of headache was highest 
under treatment with amitriptyline an additive mechanism of 
this adverse effect in chronic tension-type headache appears not 
plausible when viewed in conjunction with evidence of efficacy in 
reducing headache in these patients.
Several recommendations for the treatment of specific chronic 
pain states are available (83–89). Recommendations for the treat-
ment of chronic pain comprise TCA, pregabalin, gabapentin, and 
lidocaine as first-line treatment (84, 85, 89–91). In contrast; a sys-
temic review and meta-analysis applied a standardized grading 
system (GRADE Grading of Recommendations Assessments, 
Development, and Evaluation) to avoid bias and create evidence-
based recommendations and provided different recommenda-
tions (8, 44, 92). Recommendations for treatment of chronic 
neuropathic pain comprised duloxetine and venlafaxine, TCA 
as well as pregabalin and gabapentine as first-line therapy. 
Recommendations for venlafaxine and duloxetine were of high 
evidence, while recommendations for TCA were of moderate 
evidence. Interestingly, in the present meta-analysis venlafaxine 
was one of the substances most likely to induce adverse effects 
with high risk for the need of withdrawal. In contrast; nortrip-
tyline showed a better safety profile. No clear superiority of one 
substance over another has been shown in our analysis; selection 
of the specific drug should rather be guided by specific adverse 
effect profiles in a personalized approach which also takes 
into account the patients’ individual comorbidities and health 
status. Patients with chronic pain who have to drive or have to 
operate machinery due to their profession should preferably not 
be treated with antidepressants leading mainly to drowsiness, 
dizziness and somnolence such as mirtazapine, venlafaxine, 
nortriptyline, amitriptyline and desipramine. For those patients, 
drugs as milnacipran and duloxetine might be more beneficial. 
By contrast, patients suffering from sleep disturbances in addi-
tion to chronic pain might benefit from drugs with these adverse 
effects. However, mirtazapine is beneficial of sleep at 7.5 and 
15  mg only. Dry mouth might be particularly unpleasant in 
patients who need to speak a lot. Those patients might benefit 
more from antidepressants with low incidence of dry mouth 
such as venlafaxine and milnacipran. Some antidepressants can 
lead to cardiovascular adverse effects such as prolongation of 
QT interval, hypertension or arrhythmias. Although evidence 
on these adverse effects was low in our analysis, tachycardia 
and palpitations occurred mostly under treatment with mil-
nacipran, amitriptyline and fluoxetine. Consequently, these 
effects should be taken into consideration in patients with high 
cardiovascular risk.
Disturbance of sexual function or urinating difficulties reduce 
quality of life (93). In the present analysis, these adverse effects 
showed comparably low incidence for the analyzed drugs. This 
might be related to the fact that patients report infrequently about 
these symptoms to avoid embarrassing situations or might be due 
to the lower doses of antidepressants applied in included studies 
compared to antidepressive dosages. In the present analysis, dis-
turbance of sexual function or urinating difficulties, adverse effects 
were observed under duloxetine, desipramine, and fluoxetine.
While further elaboration of the findings from our pooled 
analyses is warranted to optimize individualized pharmacother-
apy in patients who are suffering from chronic pain, prospective 
preventive research is equally needed. In fact, specific guidelines 
exist for the conduction of prevention clinical trials in this popu-
lation that pose a useful guide to researchers (94).
cOnclUsiOn
Based on the meta-analytic comparison of adverse effect rates 
between antidepressants and placebo our study confirm toler-
ability of low-dose antidepressants for the treatment of chronic 
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pain and reveals specific profiles of adverse effects that differ from 
those of higher doses of the same drugs applied for depression. 
These findings might be useful in multimodal treatment which 
takes patient comorbidities and co-medication into consideration. 
Pathophysiology of the underlying disease, comorbidities, lifestyle, 
and co-medication should be taken into consideration when deter-
mining the use of an antidepressant in patients with chronic pain.
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